Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Pathology
Jonathan R. Fromm, Claire Tang, Kikkeri N. Naresh
Summary: Using flow cytometric analysis, it was found that the percentage of HRS cells is associated with treatment response and patient age, and the subtype also affects the proportion of B cells.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
YuanBo Xue, Xun Lai, RuiLei Li, ChunLei Ge, BaoZhen Zeng, Zhen Li, QiaoFen Fu, LiuFang Zhao, SuWei Dong, JinYan Yang, JiYin Guo, QingYin Meng, QingHua Tan, ZhenHui Li, HaiYan Ding, YanLei Zhang, ShaoHui Liu, Alex H. Chang, Hong Yao, RongCheng Luo
Summary: The study indicated that combination therapy with anti-CD19 and CD30 CAR T-cells may be safe and effective for relapsed/refractory classical Hodgkin's Lymphoma patients. Only a small percentage of patients were found eligible for this treatment, but those who received it showed promising outcomes without severe adverse events. Further clinical trials are needed to explore the potential of CD19 and CD30 CAR T-cell combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Angelica Maria Gamboa-Cedeno, Mariangeles Diaz, Nancy Cristaldo, Victoria Otero, Natalia Schutz, Dorotea Fantl, Silvana Cugliari, Marta Zerga, Erica Rojas-Bilbao, Federico Jauk, Hernan Garcia Rivello, Myriam Nunez, Stella Maris Ranuncolo
Summary: The study highlights the potential of BCL-2 as a prognostic biomarker and a new therapeutic target in classical Hodgkin Lymphoma (cHL). Additionally, it reveals the cytotoxic effect of venetoclax in human cHL cell lines for the first time.
Article
Oncology
Claire Lamaison, Juliette Ferrant, Pauline Gravelle, Alexandra Traverse-Glehen, Herve Ghesquieres, Marie Tosolini, Cedric Rossi, Loic Ysebaert, Pierre Brousset, Camille Laurent, Charlotte Syrykh
Summary: This study evaluated the dynamic expression of 586 immune-related genes in a cohort of 42 classical Hodgkin lymphoma (cHL) patients. A 19-gene immune signature predictive of cHL relapse was identified, which was strongly dependent on histological subtype.
Review
Hematology
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko, Alexandr Migas, Simon Dubovik, Natalya Konoplya
Summary: This article provides an overview of the pathogenesis of Classical Hodgkin lymphoma (cHL) and the rationale for the development of chimeric antigen receptor T cell (CAR-T cell) therapy in its treatment. The article discusses the key molecular and cellular mechanisms involved in cHL and explores strategies to enhance the efficacy and safety of CAR-T cell therapies. Furthermore, the article presents an overview of the results from clinical trials evaluating the efficacy of CAR-T cell therapies in cHL, highlighting their potential as a promising therapeutic option.
Review
Hematology
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko, Alexandr Migas, Simon Dubovik, Natalya Konoplya
Summary: This article provides an overview of the pathogenesis of classical Hodgkin lymphoma (cHL) and the rationale for CAR-T cell therapy development. It highlights the potential of CAR-T cell therapy in the treatment of cHL and summarizes the results from clinical trials evaluating its efficacy.
Article
Hematology
Alex Reza Gholiha, Peter Hollander, Ingrid Glimelius, Gustaf Hedstrom, Daniel Molin, Henrik Hjalgrim, Karin E. Smedby, Jamileh Hashemi, Rose-Marie Amini, Gunilla Enblad
Summary: IL-6 expression in the tumor microenvironment is associated with adverse survival outcomes in patients with classical Hodgkin lymphoma, while not correlated with other immune markers or serum IL-6 levels.
Review
Biochemistry & Molecular Biology
Faryal Munir, Viney Hardit, Irtiza N. Sheikh, Shaikha AlQahtani, Jiasen He, Branko Cuglievan, Chitra Hosing, Priti Tewari, Sajad Khazal
Summary: Hodgkin lymphoma is a hematological malignancy that arises from germinal-center B cells and has good overall prognosis. However, treating relapsed or resistant disease remains challenging, despite high survival rates from current treatment techniques. The development of late malignancies after successful cure poses a major concern, especially in pediatric patients. It is crucial to develop biomarkers to stratify patients and determine optimal treatment regimens to balance survival rates and late consequences. This article reviews the epidemiology, risk factors, staging, biomarkers, treatments, and late development of secondary malignancies in Hodgkin lymphoma patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Hematology
Alex Reza Gholiha, Peter Hollander, Liza Lof, Ingrid Glimelius, Gustaf Hedstrom, Daniel Molin, Henrik Hjalgrim, Karin E. Smedby, Jamileh Hashemi, Rose-Marie Amini, Gunilla Enblad
Summary: This study investigated the expression of CD47 in the tumor microenvironment of classical Hodgkin lymphoma and found that high CD47 expression was associated with poorer prognosis. Additionally, CD47 expression did not correlate with SIRPa+ leukocytes or PD-1, PD-L1, and PD-L2 expression.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Dennis A. Eichenauer, Horst Muller, Leonard Elger, Helen Goergen, Michael Fuchs, Stefanie Kreissl, Boris Boll, Volker Diehl, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Summary: NHL after cHL is a rare event that primarily affects older individuals, with a five-year event-free survival and overall survival estimates of 36.9% and 44.2% respectively.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Andrea C. Lo, Karin Dieckmann, Tanja Pelz, Eve Gallop-Evans, Rita Engenhart-Cabillic, Dirk Vordermark, Kara M. Kelly, Cindy L. Schwartz, Louis S. Constine, Kenneth Roberts, David Hodgson
Summary: Classical Hodgkin lymphoma (HL) has transformed from a fatal disease to a curable cancer over the past century, with a major focus on reducing the use of radiation therapy and chemotherapy to minimize toxicities. Treatment intensity is guided by risk category, with response to chemotherapy playing a crucial role in deciding the utilization of radiation therapy. Ongoing trials are exploring the use of immunoregulatory drugs to mitigate the toxicities of intensified chemotherapy.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Hematology
Estelle Bourbon, Pierre Sesques, Morgane Gossez, Jeremie Tordo, Emmanuelle Ferrant, Violaine Safar, Florent Wallet, Guillaume Aussedat, Alizee Maarek, Fadhela Boua, Lionel Karlin, Dana Ghergus, Camille Golfier, Helene Lequeu, Anne Lazareth, Verane Schwiertz, Sebastien Viel, Maryam Idlhaj, Herve Ghesquieres, Guillaume Monneret, Emmanuel Bachy, Fabienne Venet
Summary: Despite the success of anti-CD19 CART cells in R/R LBCL, they are associated with toxicity and a high relapse rate. This study found that low HLA-DR expression on monocytes before CAR T-cell infusion is associated with older age, poorer performance status, higher tumor burden, and elevated inflammatory markers. Patients with low HLA-DR levels had a poorer duration of response and survival.
Article
Oncology
Reyizha Nuersulitan, Mingzi Yang, Lan Mi, Meng Wu, Xin Liu, Lingyan Ping, Yan Xie, Weiping Liu, Yuqin Song, Jun Zhu
Summary: The study demonstrates that the survival probability of patients with classical Hodgkin's lymphoma increases over time while the hazard of failure decreases gradually. Early-stage patients have lower failure hazard rates, and advanced-stage patients also experienced significant decreases in failure hazard rates after 3 years.
CANCER MANAGEMENT AND RESEARCH
(2021)
Editorial Material
Medicine, General & Internal
Dan L. Longo, James O. Armitage
Summary: Treatment for Hodgkin's lymphoma has been a success in modern medicine. The once fatal disorder is now curable in the majority of patients, even in advanced stages. The focus of treatment is on maintaining high cure rates while reducing toxic effects. The best approach for advanced-stage, high-risk patients is currently debated.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
